Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jonathan B. Rost"'
Autor:
Keaton C. Stoner, Caterina Florissi, Rebecca Gowen, Jonathan B. Rost, Sara Suhl, Richard Thomas Wood
Publikováno v:
Diabetes. 69
Social support plays an important role in both mental and physical well-being. This study used patient-reported outcomes to better understand the effect of social support and diabetes communities on the behaviors and health outcomes of those living w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b959cf329496b413c138b4a09025fb67
https://doi.org/10.2337/db20-737-p
https://doi.org/10.2337/db20-737-p
Autor:
Keaton C. Stoner, Caterina Florissi, Sara Suhl, Jonathan B. Rost, Rebecca Gowen, Richard J. Wood
Publikováno v:
Diabetes. 69
SGLT2 inhibitors are not approved for people with type 1 diabetes in the U.S. due to elevated risk of diabetic ketoacidosis (DKA), prompting interest in ketone testing education. This study surveyed 4,612 people with type 1 diabetes across the U.S.,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::565c01839dad84b2655ad9dd5f38c1ad
https://doi.org/10.2337/db20-676-p
https://doi.org/10.2337/db20-676-p
Autor:
Jonathan B. Rost, Payal H. Marathe, Keaton C. Stoner, Ann M. Carracher, Caterina Florissi, Jeemin Kwon, Emily Fitts, Peter J. Rentzepis, Divya Gopisetty, Martin J. Kurian, Kelly L. Close, Richard Thomas Wood, Irl B. Hirsch, Mikhail Kosiborod
Publikováno v:
Diabetes. 68
Cardiovascular disease (CVD) is a leading cause of death in people with type 2 diabetes (T2D). Recent cardiovascular (CV) outcomes trials have shown CV benefits for several GLP-1 receptor agonists and SGLT2 inhibitors. We aimed to evaluate T2D patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32b4d24e830c36d56db74e1ba620dcdf
https://doi.org/10.2337/db19-1477-p
https://doi.org/10.2337/db19-1477-p
Publikováno v:
Metabolism. 104:154129
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f6a4f0a30ca5b2464145d82dafc94f3
https://doi.org/10.1016/j.metabol.2019.12.075
https://doi.org/10.1016/j.metabol.2019.12.075